| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2607 |
| Trial ID | NCT04780659 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Phase | Phase4 |
| Recruitment status | Active, Not Recruiting |
| Title | Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study |
| Year | 2021 |
| Country | Sweden |
| Company sponsor | Karolinska University Hospital |
| Other ID(s) | 2021-000175-37 |
| Vector information | |||
|
|||
| Cohort1: Healthy controls | |||||||||||
|
|||||||||||
| Cohort2: PID | |||||||||||
|
|||||||||||
| Cohort3: HIV | |||||||||||
|
|||||||||||
| Cohort4: HSCT/CAR-T | |||||||||||
|
|||||||||||
| Cohort5: SOT | |||||||||||
|
|||||||||||
| Cohort6: CLL | |||||||||||
|
|||||||||||